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Abstract
Long noncoding RNAs (lncRNAs) are emerging as regulators of gene
expression in pathogenesis, including cancer. Recently, lncRNAs
have been implicated in progression of specific subtypes of breast
cancer. One aggressive, basal-like subtype associates with increased
EGFR signaling, while another, the HER2-enriched subtype, engages
a kin of EGFR. Based on the premise that EGFR-regulated lncRNAs
might control the aggressiveness of basal-like tumors, we identified
multiple EGFR-inducible lncRNAs in basal-like normal cells and over-
laid them with the transcriptomes of over 3,000 breast cancer
patients. This led to the identification of 11 prognostic lncRNAs.
Functional analyses of this group uncovered LINC01089 (here
renamed LncRNA Inhibiting Metastasis; LIMT), a highly conserved
lncRNA, which is depleted in basal-like and in HER2-positive tumors,
and the low expression of which predicts poor patient prognosis.
Interestingly, EGF rapidly downregulates LIMT expression by
enhancing histone deacetylation at the respective promoter. We
also find that LIMT inhibits extracellular matrix invasion of
mammary cells in vitro and tumor metastasis in vivo. In conclusion,
lncRNAs dynamically regulated by growth factors might act as novel
drivers of cancer progression and serve as prognostic biomarkers.
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Introduction
Growth factors and their receptor tyrosine kinases (RTKs) play major
roles in breast cancer progression (Hynes & Watson, 2010; Witsch
et al, 2010). Of the five major breast cancer subtypes represented in
the Prediction Analysis of Microarrays (PAM50) subtyping (Parker
et al, 2009), the one overexpressing the RTK called HER2 and the less
prevalent, the basal-like subtype are considered highly aggressive
(Perou et al, 2000). While the former is driven by an amplified HER2
gene, a fraction of the basal subtype is characterized by relatively high
abundance of the epidermal growth factor receptor (EGFR, a kin of
HER2) (Carey et al, 2010; Foulkes et al, 2010). In line with driver
functions, EGFR-associated poor prognostic signatures are highly
expressed in basal-like tumors, and blocking EGFR using either kinase
inhibitors or monoclonal antibodies effectively retards growth of
basal-like cancer cells (Hoadley et al, 2007; Ferraro et al, 2013).
Using basal-like untransformed cells, MCF10A, as a model
system, data from our laboratory showed that both mRNAs and
microRNAs exhibit dynamic changes in expression following EGF
stimulation (Amit et al, 2007; Avraham et al, 2010; Kostler et al,
2013). We further demonstrated that the inducible mRNAs and
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microRNAs are embedded into regulatory subnetworks, which are
deregulated in diverse tumor types. Considering the emerging roles
for long noncoding RNAs (lncRNAs) in metastasis of breast cancer
(Serviss et al, 2014), we raised the possibility that some EGF-inducible
lncRNAs might play a role in basal-like breast cancer. LncRNAs are
transcripts greater than 200 nucleotides, which lack functional open-
reading frames (Ponting et al, 2009; Rinn, 2014). They might regulate
either local genomic regions (cis-regulation), which characterizes
lncRNA ANRIL, or distant regions of the genome (transregulation),
as in the case for lncRNA HOTAIR (Rinn et al, 2007). In addition,
lncRNAs may act as scaffolds or as decoys. These interactions might
regulate transcriptional mechanisms, including through epigenetic
silencing (Gupta et al, 2010) or transcription activation (Orom et al,
2010). LncRNAs might also act post-transcriptionally, by sequester-
ing microRNAs, or by controlling RNA processing and stability. This
large functional diversity underlies the involvement of lncRNAs in a
myriad of cellular processes, such as apoptosis (Hung et al, 2011)
and metastasis (Gutschner et al, 2013).
In accordance with multiplicity of molecular targets, lncRNAs
have been associated with several types of cancer (Gutschner &
Diederichs, 2012; Niland et al, 2012), in which they might act as
potential oncogenes or tumor-suppressor RNAs (Huarte & Rinn,
2010; Gibb et al, 2011). Moreover, because several lncRNAs can
profoundly control transcription, their profiling might assist diagno-
sis, prognosis, or biomarker identification (Wang et al, 2011a,b).
The involvement of lncRNAs in breast cancer progression is of parti-
cular interest (Shore et al, 2012). In the context of breast cancer,
HOTAIR is upregulated in tumors (Gibb et al, 2011) and its overex-
pression might serve as an independent predictor of progression-free
survival (Gupta et al, 2010). Similarly, LSINCT5, a polyadenylated
stress-induced RNA, is overexpressed in breast cancer and affects
cellular proliferation (Silva et al, 2011).
Since our model of EGF-stimulated mammary epithelial cells
mirrors gene expression patterns in breast cancer patients, it has been
employed herein with the aim of uncovering involvement of specific
lncRNAs in progression of the basal-like subtype. To this end, we
profiled EGF-induced changes in expression of lncRNAs and surveyed
the prognostic value of individual, EGF-responsive genes. This led to
the identification of a subset of eleven EGF-regulated lncRNAs, the
expression patterns of which could be used to predict survival time of
breast cancer patients. In vitro studies of the selected lncRNAs
identified LINC01089/LIMT (LncRNA Inhibiting Metastasis), a hith-
erto uncharacterized EGF-downregulated lncRNA, as a regulator of
mammary cell migration and invasion. Correspondingly, animal stud-
ies have shown that depletion of LIMT enhances metastasis formation
in vivo. Importantly, we found that downregulation of LIMT charac-
terizes breast cancer patients diagnosed with either basal-like or
HER2-enriched tumors. Taken together, these results ascribe potential
roles for inducible lncRNAs like LIMT in tumor progression.
Results
Expression levels of lncRNAs dynamically change upon
stimulation of mammary cells with a growth factor
To uncover the potential involvement of lncRNAs in breast cancer
metastasis, we first studied transcriptional responses of lncRNAs to
EGF stimulation. MCF10A human mammary cells were treated with
EGF for increasing time intervals (see scheme in Fig 1A). Purified
RNA was then used to profile expression of both lncRNAs and
mRNAs by means of gene expression microarrays. For each probe,
we calculated the change in expression at every time point, relative
to time zero (i.e. no EGF stimulation). Our initial survey noted that
the overall dynamic range of lncRNAs was smaller than the dynamic
range corresponding to mRNAs (i.e. log2 fold change ranged from
3.67 to 10.36 for mRNAs and from 2.32 to 6.94 for lncRNAs).
Because of the narrower dynamic range of lncRNAs, transcripts
were considered dynamic if their fold change was > 1.5 (lncRNAs)
or 2 (mRNAs) in at least one time point relative to time zero.
Accordingly, the expression of 346 lncRNAs was affected by EGF
(Fig 1B, left panel). Clustering the responsive lncRNAs according to
peak expression times identified waves of transcription, similar to
those observed with mRNAs (Fig 1B, right panel) and with miRNAs
(Avraham et al, 2010). Unlike mRNA, the majority of lncRNAs
exhibited downregulation in response to EGF stimulation. However,
similar to mRNAs, many lncRNAs displayed very rapid responses;
their down- or upregulation initiated as early as 20 min after stimu-
lation (confirmed by use of quantitative PCR; Fig EV1). These early
events are of special interest as they might represent immediate
responses to EGF signaling, rather than later, indirect effects of the
signaling cascade. In conclusion, the abundance of a group of
lncRNAs dynamically changes following short treatments of
mammary cells with a growth factor.
The abundance of EGF-regulated lncRNAs predicts clinical
outcome of breast cancer patients
Next, we assessed clinical cohorts for expression of the EGF-
regulated lncRNAs from MCF10A cells. Two datasets of breast
cancer patients were analyzed: The METABRIC dataset (Curtis et al,
2012) and several breast cancer cohorts integrated into a single
dataset, called “Kaplan–Meier (KM) plotter” (Gyorffy et al, 2010).
Each dataset includes ~2,000 breast cancer patients, who were
followed for > 20 years from initial diagnosis. In addition to gene
expression data, derived from either Illumina (Curtis et al, 2012) or
Affymetrix (Gyorffy et al, 2010) hybridization arrays, each
dataset also includes information on relapse-free and overall patient
survival time. A Kaplan–Meier (KM) survival curve was generated
for each of the EGF-responsive lncRNAs. This analysis identified
eleven EGF-regulated lncRNAs, the expression of which was found
to be significantly associated with patients’ survival (adjusted
P-value < 0.05), in at least one dataset (Fig EV2). Figure 2A presents
the kinetics of abundance alterations of two such early response
lncRNAs, LIMT and LOC388796. Interestingly, while low expression
of the EGF-downregulated lncRNA called LIMT predicted shorter
overall and relapse-free patient survival (Fig 2B), high expression of
LOC388796, which is upregulated in response to EGF, predicted
poor patient prognosis (Fig EV2).
Although some lncRNAs encode short peptides, and they might
occupy ribosomes, most lncRNAs possess significantly lower coding
potentials as compared to protein-coding genes (Dinger et al, 2008;
Guttman et al, 2013; Ruiz-Orera et al, 2014). In order to verify that
the eleven EGF-regulated transcripts identified above were indeed
noncoding, we examined their coding probability using the Coding-
Potential Assessment Tool—CPAT (Wang et al, 2013). As reference,
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we used coding potentials of 4,000 protein-coding RNAs and 4,000
known lncRNAs. Interestingly, the coding probabilities of all eleven
lncRNAs we identified were similar to those of known lncRNAs and
significantly lower than those of coding RNAs (Fig 2C). In addition,
the evolutionary conservation of the 11 genes displayed wide varia-
tion, with LIMT being the most conserved (Fig 2D). In summary,
we identified several noncoding RNAs, some of which are evolu-
tionarily conserved. All these lncRNAs undergo abundance alter-
ations in response to short treatments of human mammary cells
with EGF, which might predict disease aggressiveness and patient
outcome.
LIMT, an EGF-downregulated lncRNA, acts as an inhibitor of
motility in vitro and retards metastasis in an animal model
Knocking down the expression of specific lncRNAs might uncover
their cellular functions. Hence, we transfected MCF10A cells with
lncRNA-specific siRNAs (available for nine out of the 11 clinically
relevant lncRNAs) and measured knockdown efficiency using qPCR
(Fig EV3A). Because efficient knockdown was achieved for
LINC01089/LIMT, LOC642852, LOC344595, and LOC282997, the
cellular functions of these genes were addressed using apoptosis
and viability assays (Fig EV3B). Transfection with polo-like kinase
1 (PLK1)-specific siRNAs was used as reference, since knockdown
of PLK1 usually leads to extensive apoptosis. In terms of viability
and apoptosis, the only effect we observed was a slight increase in
the fraction of dying cells following knockdown of LOC282997 (aka
PDCD4-AS1, Fig EV3B), implying that the examined lncRNAs are
not involved in cell survival or apoptosis.
Since MCF10A cells adopt migratory phenotypes in response to
EGF-induced stimulation (Tarcic et al, 2012), we examined the
effect of lncRNA knockdown on cellular motility. Firstly, we
placed siRNA-transfected cells in the upper compartment of Tran-
swell migration chambers and determined their migration to the
lower compartment, 20 h later, in the presence of EGF. In this
assay, EGFR-specific siRNAs were used as reference, and indeed,
we observed strong inhibition of cellular migration following EGFR
knockdown (86%; Fig EV3C). Knockdown of only one lncRNA,
LIMT, caused a similarly large, but opposite effect on migration
(Figs 3A and EV3C). Consistent with this observation, knockdown
of LIMT also increased the capacity of cells to invade through a
layer of extracellular matrix (Fig 3B). To complement this loss-of-
function approach, we created an MCF10A subline stably
overexpressing LIMT (or eGFP as control; see Fig EV3D). As
expected, ectopic expression of LIMT reduced migratory and inva-
sive capacities (Fig 3A and B). To further validate the effect of
LIMT on migration, we designed two shRNAs directed against dif-
ferent parts of the gene and show results for sh716, because it
could more effectively downregulate the respective transcript
(Fig EV3E, see Materials and Methods). Consistent with the obser-
vations made with siRNAs and with overexpression of LIMT,
MCF10A cells stably expressing shLIMT displayed remarkably
increased migration and invasion relative to control cells (Fig 3A
and B).
Taken together with the ability of EGF to decrease expression
of LIMT (Fig 2A), the migration and invasion results proposed
the following scenario: EGF treatment downregulates LIMT, an
inhibitor of cell migration and invasion, thereby enhancing motil-
ity of mammary cells. To test this model, we used a chemical
inhibitor, U0126, which specifically blocks a major signaling
pathway downstream of EGFR, the RAS-to-ERK pathway. We first
confirmed blocking efficacy by assaying ERK phosphorylation
A
B
Figure 1. EGF stimulation instigates dynamic changes in expression of multiple lncRNAs.
A A scheme of the experimental design. Triangles represent the time points (in minutes) of cell harvesting for RNA purification, after EGF stimulation (GF, growth factor).
B MCF10A cells were stimulated with EGF (10 ng/ml) for up to 8 h. At the indicated time points, cells were harvested, and RNA was isolated and used to determine
expression levels of specific lncRNAs and mRNAs, using the SurePrint microarray platform (from Agilent). The heatmaps depict lncRNAs (left) and mRNAs (right) for
which a > 1.5-fold (lncRNAs) or a > twofold (mRNA) change in expression was observed in at least one of the time points, compared to unstimulated cells (time zero).
Note that each row of the heatmap represents an individual lncRNAs/mRNAs, and values (see color scale at the bottom) indicate the log2 ratio of RNA levels between
each time point and time zero.
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(Fig 3C), as well as by measuring mRNA levels of EGR1, a
downstream target of the RAS-to-ERK pathway (Fig EV3F). Ulti-
mately, we measured RNA levels of LIMT and found that inhibit-
ing the ERK pathway, using the MEK inhibitor, negated the
decrease in abundance of LIMT (Fig 3D). This observation
suggests that the RAS-to-ERK pathway mediates EGF-induced
downregulation of LIMT, as well as the consequent enhancement
of cellular motility.
Since high abundance of LIMT is associated with longer
survival of advanced state breast cancer patients (Fig 2B and
Appendix Fig S1), we tested the prediction that overexpression of
LIMT would attenuate metastasis in vivo. For this, we established
a derivative of the highly metastatic MDA-MB-231 triple negative
breast cancer cell line, which stably expresses an ectopic LIMT (or
eGFP). As a prelude to the metastasis assays, we validated that
manipulating the abundance of LIMT in MDA-MB-231 can imitate
the migration effects we observed with MCF10A cells (Fig EV4).
Next, we injected RFP-labeled MDA-MB-231 cells overexpressing
LIMT (or eGFP) into the tail vein of female SCID mice. Eighteen
days after injection, lungs were excised and the number of meta-
static nodules was quantified. Consistent with the in vitro results,
overexpression of LIMT reduced the number of detectable meta-
static nodules (Fig 4A), supporting a role for LIMT in inhibiting




Figure 2. Changes in abundance of EGF-regulated lncRNAs correlate with clinical outcome of breast cancer patients.
A Shown are levels of two EGF-regulated lncRNAs: the EGF-downregulated lncRNA called LIMT (left) and the upregulated lncRNA called LOC388796 (right). RNA
abundance was determined using microarrays (red) and real-time qPCR (blue) and presented as fold change relative to time zero. Beta-2-microglobulin was used for
normalization.
B Shown are Kaplan–Meier plots of overall survival and relapse-free survival for the EGF-regulated lncRNA called LIMT. To obtain the data, we overlapped the list of
EGF-regulated lncRNAs with the METABRIC clinical dataset (Illumina platform; left panel) and the KM-plotter dataset (Affymetrix platform; right panel). The red and
blue lines of the left panel correspond to high and low expressors, respectively (each shows one-third of the population; 1129 out of a total of 1,693 patients). The
same applies to the right panel, except that the population was divided into two equal size groups (N = 1,660 patients).
C Coding potentials of clinically significant lncRNAs were calculated using CPAT, and they are individually presented along with the mean coding probabilities of
control groups of protein-coding RNAs and lncRNAs (in blue). Note that two variants of LINC00472 and LINC00652 are presented.
D Evolutionary conservation of the primary nucleotide sequences of the clinically significant EGF-regulated lncRNAs was calculated using PhyloP across 100
vertebrates. Individual conservation scores are presented along with that of control groups of protein-coding RNAs and noncoding RNAs (in blue).
ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 9 | 2016
Aldema Sas-Chen et al EGF-inducible lncRNAs in aggressive breast cancers EMBO Molecular Medicine
1055
Published online: August 1, 2016 
employed a reciprocal approach utilizing MDA-MB-231 cells stably
expressing the selected shRNA specific to LIMT. As predicted, cells
stably expressing shLIMT (sh716) displayed relatively high migra-
tory capacity in vitro (Fig EV4). Hence, both knocked-down cells
and control cells were then subjected to the above-described
in vivo metastasis assay. Analyses of fluorescence images of the
lungs from the LIMT knockdown group confirmed the ability of
LIMT to inhibit metastasis of mammary cells from the circulation
to lungs (Fig 4B). Overall, two independent lines of animal studies
attributed to this EGF-downregulated lncRNA an important role in
regulating metastasis formation; hence, we denoted it as LIMT
(LncRNA Inhibiting Metastasis).
The 50 region of LIMT is highly conserved in vertebrates and
undergoes histone deacetylation in response to EGF
To gain deeper understanding of LIMT, we explored its genomic
characteristics. LIMT maps to chromosome 12, between the
protein-coding genes SETD1B and RHOF. In accordance with
earlier reports (Ulitsky et al, 2011), the human LIMT gene is
highly conserved throughout most of its length, with its 50 portion
(which encodes the first four exons) showing a very high degree
of conservation in vertebrates (Fig 5A, green rectangle). This
observation hints that a cellular function of LIMT, such as recog-
nition of other molecules, might localize to the transcript’s 50
region. Because LIMT is dynamically expressed in mammary
cells, we predicted the presence of histone modifications at the 50
region. Analyses of histone marks characteristic of transcription-
ally active, open chromatin structures, such as H3K4Me3, in the
vicinity of the transcription start site of LIMT, were consistent
with an active promoter (Fig 5A). To corroborate this observa-
tion, we investigated changes in tri-acetylation of histone 3
(lysine 27; H3K27Ac), a marker of transcriptional activity. This
was done by immunoprecipitating H3K27Ac from MCF10A cells,
after stimulation with EGF. Profiling immunoprecipitated DNA
fragments using deep sequencing detected an overall decrease in
acetylation of histone 3 at lysine 27, especially at the 50 region,
as early as 20 min post-stimulation (Fig 5A, red rectangle). This
observation is consistent with the observed EGF-induced reduc-
tion in transcript abundance (Fig 2A). Interestingly, although
some lncRNAs have been shown to affect the expression of




Figure 3. The ERK pathway mediates the effect of EGF on LIMT, which normally inhibits mammary cell migration and invasion.
A, B MCF10A cells were transfected with LIMT-specific siRNAs (or with control siRNA), and their migration (A, left panels) or invasion (B, left panels) were determined.
Likewise, cells were stably transfected with plasmids encoding for shRNAs against LIMT (middle panels) or with plasmid encoding for either LIMT or eGFP (Control).
Also shown is quantification of cell migration and invasion upon lncRNA knockdown and overexpression (OX). P-values of one-way ANOVA are presented. Each
assay was repeated at least three times.
C, D MCF10A cells were treated for 30 min with U0126 (a MEK inhibitor), or with no agent, and thereafter, EGF was added (10 ng/ml) and incubated with cells for
additional 30 min (C) or 4 h (D). Protein extracts were used to assess levels of phosphorylated ERK (C). Isolated RNA was used to determine abundance of LIMT
using real-time qPCR (D). Expression values are presented as fold change relative to time zero. Beta-2-microglobulin was used for normalization. P-value of t-test
from four repeats is shown.  : no EGF, + : EGF for 4 h.
Data information: All values represent mean  SD of replicates.
Source data are available online for this figure.
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weak correlation with transcript levels of the flanking genes,
namely SETD1B and RHOF (Fig EV5A and B). This observation
suggests that expression of LIMT is uncoupled from that of the
neighboring, protein-coding genes.
Identification of candidate LIMT-regulated genes
Because lncRNAs might act as scaffolds or decoys, which interact
with microRNAs (Poliseno et al, 2010; Yuan et al, 2014) and the
epigenetic machinery (Rinn, 2014) to regulate transcription, we
explored potential downstream targets of LIMT. To this end, we
firstly manipulated the levels of LIMT in MCF10A cells, by means
of either siRNA-mediated knockdown or stable overexpression.
We then profiled genomewide abundance of RNAs using Affyme-
trix microarrays. Analysis of the microarray screens identified 48
genes that undergo reciprocal expression changes in response to
LIMT knockdown and overexpression (i.e. at least a 1.5-fold
change in expression compared to control; Fig EV5C). Remark-
ably, the selected group of genes included several noncoding
RNAs and coding genes, such as TGFB2, SERPINB2, PTPRZ1,
RHOB and IL-24, which are known to be regulators of cellular
migration. Future studies will test direct or indirect interactions
between LIMT and the respective promoters, or their chromatin
marks.
LIMT displays wide tissue distribution and reduced expression in
relatively aggressive breast tumors
The finding that LIMT is downregulated in response to EGFR
signaling and the ability of LIMT to inhibit metastasis in animal
models correspond to our observations associating reduced LIMT
expression with poor prognosis of breast cancer patients
(Fig 2B). This corollary led us to explore LIMT’s expression
patterns. As a first step, we analyzed a panel of 44 cell lines
representing cancer and non-cancer cells from 15 tissues of
human origin, including six breast cell lines. LIMT was found to
be widely and differentially expressed, with relatively high
expression in brain, blood, and several lung and mammary cell
lines (Fig 5B).
Next, we evaluated relations between LIMT and molecular
subtypes of breast cancer, in two cohorts of patients: the Oslo2
cohort (Aure et al, 2014) and the larger, METABRIC dataset (Curtis
et al, 2012). In line with the aforementioned lines of evidence, the
lowest expression of LIMT in both cohorts corresponded
A
B
Figure 4. LIMT inhibits metastasis formation in vivo.
A RFP-labeled MDA-MB-231 cells stably overexpressing LIMT or eGFP were injected into the tail vein of 5-week-old female SCID mice (150,000 cells/mouse). Eighteen
days after injection, lungs were excised and imaged. The number of metastatic nodules in each lung was quantified and presented in a dot plot. The horizontal lines
represent median number of nodules per animal of each group. Each dot of the left panel represents one animal. The experiment was repeated twice (N = 18 and 14
for LIMT and eGFP overexpression, respectively). Shown are representative fluorescence images of lungs from the LIMT overexpression group and the control group.
Scale bar, 0.5 cm. A two-way ANOVA was applied to evaluate differences between groups.
B The experiment described above was carried out with RFP-labeled MDA-MB-231 cells stably expressing shRNAs against LIMT (N = 7) or control shRNAs (N = 8).
Shown are representative fluorescence images of lungs from the LIMT knockdown group and the control group. Scale bar, 0.5 cm. A Student’s t-test was applied to
evaluate differences between groups. The experiment was repeated with a second shRNA and yielded similar results.
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A
B
Figure 5. Features of the LIMT gene and RNA abundance in cell lines of different tissues of origin.
A Schematic representation of the annotated RefSeq gene models of LIMT (NR_002809; chromosome 12q24.31) and the neighboring protein-coding genes (RHOF and
SETD1B). Arrows denote direction of transcription (note that LIMT resides on the minus strand). Also shown is the distribution of evolutionary conservation along the
sequence of LIMT across 100 vertebrate species. Note that the 50 region of LIMT is highly conserved (green rectangle). Promoter-associated histone methylation
(H3K4Me3) and acetylation (H3K27Ac3) were obtained in MCF7 and MCF10A cells, respectively (see Materials and Methods). Acetylation signals were obtained for
MCF10A cells stimulated with EGF for 20 min (green), or unstimulated (black; overlaying histogram). Note that stimulation with EGF caused a decrease in acetylation
at the promoter region (red rectangle).
B Expression of LIMT was determined in a panel of 44 cancer and non-cancer cell lines using real-time qPCR. Expression levels were normalized to the GAPDH
transcript and presented in arbitrary units (A.U.). N, non-cancer cell line.
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to patients diagnosed with basal-like cancer (Fig 6A and
Appendix Fig S1), an aggressive tumor frequently associated with
high EGFR expression and mutations in the downstream pathways
(Hoadley et al, 2007; Foulkes et al, 2010). Similarly, low expres-
sion of LIMT was noted in the other aggressive subgroup, HER2
enriched. In line with reduced expression in relatively aggressive
tumors, low LIMT expression correlated with higher tumor grade
and stage, HER2 positivity and ER negativity (Fig 6B–D and
Appendix Fig S1). In conclusion and in line with the analyses of
patient survival, we performed on additional cohorts, the loss of
LIMT might coincide with the acquisition of aggressive features by
breast cancers.
In summary, by investigating a model system that simulates
autocrine and stromal mechanisms controlling invasion of
mammary tumor cells across tissue barriers, we identified several
lncRNA molecules, the expression of which is altered in response to
a growth factor and might predict disease course. Focusing on one
of these, LIMT (LINC01089), we obtained evidence in support of an
EGF-induced, ERK-mediated downregulation of this noncoding RNA
molecule. Manipulating LIMT’s transcript levels inhibited the ability
of mammary cells to migrate in vitro, as well as altered their ability
to form metastases in mice. In line with clinical relevance of the
EGFR–ERK–LIMT regulatory module, reduced expression of LIMT
marks mammary tumors of patients diagnosed with relatively
aggressive and advanced forms of the disease. Below, we discuss
potential mechanisms and clinical implications of LIMT and other
growth factor-responsive lncRNAs.
Discussion
Breast cancer is a heterogeneous disease; hence, many efforts are
being made to identify new drivers and classify tumors into increas-
ing numbers of subtypes (Perou et al, 2000; Dawson et al, 2013).
Thus, whereas initial profiling focused on finding histological char-
acteristics and signatures of protein-coding genes, more recent stud-
ies have found that the expression of microRNAs may also assist
prognosis and classification (Dvinge et al, 2013). Importantly, the
relatively high tissue specificity of lncRNAs promises a role for these
noncoding RNAs as drivers and biomarkers of breast cancer (Wang
et al, 2011a). For example, a recent survey of 658 infiltrating ductal
tumors reported that the lncRNA HOTAIR was significantly overex-
pressed in the HER2-positive subgroup, while the lncRNA
HOTAIRM1 was significantly overexpressed in the basal-like
subgroup (Su et al, 2014).
Herein, we introduce a novel approach based on the identifi-
cation of inducible lncRNAs. Our focus on growth factor-




Figure 6. Expression of LIMT in breast cancer specimens associates with disease parameters.
A–D The expression of LIMT is shown relative to (A) PAM50 subtypes (N = 381 patients), (B) tumor grade (N = 309), (C) HER2 status (N = 309), and (D) ER
status (N = 381 patients). Expression of the lncRNA was determined in tumors from breast cancer patients of the Oslo2 study using Agilent arrays.
Molecular subtypes of the corresponding tumors were determined by using the PAM50 classifier. The Student’s t-test was applied to evaluate differences
in lncRNA expression between two groups. To evaluate differences in expression among three or more groups, we applied one-way analysis of variance
(ANOVA). The bottom and top of the box represent the first and third quartiles of the data, respectively, and the band inside the box represents the
median of the data. The lower and upper whiskers represent the lowest and highest data points of the data, respectively. Circles represent outliers,
defined as samples deviating by more than 1.5× interquartile range (IQR) from the upper or lower quartiles, respectively.
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stroma and growth factors in multiple steps of tumor progression
(Witsch et al, 2010), including progression of basal-like tumors
(Foulkes et al, 2010). Hence, expression of the EGF-inducible
lncRNAs we uncovered was examined in large cohorts of
breast cancer patients, with the vision of identifying potential
drivers and biomarkers of the basal-like and the HER2-enriched
subtypes. The unbiased screen identified several EGF-responsive
lncRNAs, which have previously been associated with cancer
progression, demonstrating the suitability of our approach. For
example, Neat1, which is overexpressed in advanced ovarian
carcinoma and assists diagnosis (Pils et al, 2013), and LINC00472,
high expression of which is correlated with reduced risk of relapse
and death of breast cancer patients (Shen et al, 2015). Importantly,
both lncRNAs were found to be early responders to EGF in our
cellular model.
Notably, the analysis we performed also identified new candidate
lncRNAs, with potential roles in breast cancer progression and pro-
filing. Functional assays of the candidates, which made use of RNA
interference, led us to focus on a previously uncharacterized
lncRNA, referred herein as LIMT (originally denoted as LINC01089
or LOC338799). We found that downregulation of this lncRNA
depends on prior activation of EGFR and the RAS-to-ERK pathway.
Notably, this signaling route is frequently activated in hormone-
independent breast cancer and serves as a driver of mammary cell
migration (Tarcic et al, 2012). Accordingly, we found that knock-
down of LIMT enhanced cellular migration and invasion in vitro, as
well as metastasis in vivo. Because lncRNAs such as ANRIL, SRG1
and Paupar might regulate in cis the expression of nearby genes
(Martens et al, 2004; Kotake et al, 2011), we investigated whether
LIMT’s neighbors, namely the protein-coding genes RHOF (posi-
tioned 1,579-bp downstream of LIMT) and SETD1B (located on the
opposite strand to LIMT, at a distance of 1,248 bp), are co-expressed
in tumors. However, expression of these genes did not correlate to
that of LIMT.
Understanding the mechanisms by which LIMT regulates cellular
migration and tumor progression is a matter of further investigation.
Because LIMT, and especially its 50 region, is one of only
29 lincRNAs that display very high sequence conservation through-
out all vertebrates (Ulitsky et al, 2011), we assume that LIMT’s
function is shared by several species and that it requires a specific
structure at the 50 region. Presumably, physical interactions of LIMT
with protein or RNA molecules regulate transcription of coding and
noncoding genes involved in cellular motility. Some of these genes
may appear in the groups we identified by applying array technol-
ogy on LIMT-manipulated mammary cells. Alternatively, like
several other lncRNAs, LIMT might interact with the epigenetic
machinery (Rinn, 2014). Current studies also uncover binding of
lncRNAs with microRNAs (Poliseno et al, 2010; Yuan et al, 2014),
and yet other studies unearth roles of peptides encoded by short
open-reading frames present within putative lncRNAs (Bazzini et al,
2014; Ruiz-Orera et al, 2014). Regardless of the underlying mecha-
nism, reduced expression of LIMT emerges from the present study
as a trait of relatively aggressive, basal-like and HER2-driven breast
tumors. In the same vein, we found that LIMT is downregulated in
grade 3 and in stage 4 mammary tumors compared to less advanced
tumors. Thus, LIMT might represent a new class of EGF-controlled
and ERK-mediated inhibitors of breast cancer metastasis, which
function as tumor-suppressor lncRNAs.
Materials and Methods
Materials and cell lines
MCF10A cells were grown as described (Tarcic et al, 2012). For time
course experiments, cells were starved overnight in DME:F12 (1:1)
medium without additives (starvation medium) and at the time of
stimulation, EGF was added to a final concentration of 10 ng/ml.
MDA-MB-231 cells were grown in DME medium supplemented with
10% fetal calf serum. The listed 44 normal and cancer cell lines
were cultured in their respective media and supplements
(Appendix Table S1). An anti-ERK2 rabbit polyclonal antibody was
purchased from Santa Cruz Biotechnology. The anti-phosphorylated
ERK1/2 antibody was purchased from Promega. The goat anti-rabbit
IgG conjugated to horseradish peroxidase (HRP) was purchased
from Jackson ImmnoResearch Laboratories. A rabbit polyclonal
antibody to the acetylated form (lysine 27) of histone 3 was
purchased from Abcam (ab4729).
RNA purification and real-time quantitative PCR
RNA isolation was performed using the TRIzol reagent (Life Tech-
nologies) or the PerfectPure RNA Cultured Cells kit (5 Prime).
Generation of cDNA was performed using either qScript cDNA
synthesis kit (Quanta), High-capacity cDNA reverse transcription kit
(Applied Biosystems) or RevertAid Reverse Transcriptase (Thermo
Scientific). Real-time qPCR analysis was performed using Fast SYBR
Green Master Mix (Applied Biosystems). Primers were designed
using PrimerBlast, and their sequences appear in
Appendix Table S2. Transcripts encoding beta-2 microglobulin
(B2M) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were used for normalization.
Lysate preparation and immunoblotting analyses
Cells were harvested in solubilization buffer (50 mM HEPES (pH
7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM
EDTA, 1 mM EGTA, 10 mM NaF, 30 mM beta-glycerol phos-
phate, 0.2 mM Na3VO4, and a protease inhibitor cocktail).
Heated (95°C) lysates were loaded onto acrylamide gels and
resolved using electrophoresis, followed by electrophoretic trans-
fer to a nitrocellulose membrane. After transfer, nitrocellulose
membranes were blocked in TBST buffer (0.02 M Tris–HCl (pH
7.5), 0.15 M NaCl, and 0.05% Tween-20) containing 5% low-fat
milk, blotted overnight using a primary antibody, washed in
TBST, and incubated for 30 min with a secondary antibody
linked to HRP.
siRNA oligonucleotides and transfection methods
The siRNA oligonucleotide was purchased from Dharmacon. For
knockdown experiments, cells were seeded in 6-well plates at 50%
confluence, and 24 h later, they were transfected with siRNAs
(20–50 nM) using the Lipofectamine 2000 transfection reagent (Life
Technologies). Forty-eight hours later, cells were harvested and
RNA was purified in order to verify knockdown efficiency using
real-time qPCR. Sequences of siRNA oligonucleotides are presented
in Appendix Table S3.
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Plasmids and infections
For overexpression of LIMT, the nucleotide sequence of LINC01089/
LIMT (NR_002809) was purchased from BlueHeron and cloned into
a pLEX_307 expression vector. As control, eGFP was cloned into
pLEX_307. For knockdown of LIMT: Sequences targeting LIMT were
designed using siRNA Wizard (http://www.invivogen.com/
sirnawizard) and the GPP site (http://www.broadinstitute.
org/rnai/public), as well as sequences designed by Dharmacon for
siRNAs. Each shRNA sequence was cloned into a pLKO.1 plasmid
(Addgene #10878). An shControl pLKO.1 plasmid was used as
control (Addgene #10879). Sequences of shRNAs appear in
Appendix Table S3. Lentiviruses encapsulating the LIMT expression
vector or the shRNA expression vectors (along with the respective
controls) were produced in HEK-293FT cells and used to infect
MCF10A or RFP-labeled MDA-MB-231 cells. Selection of cells was
done using puromycin.
Cell migration and invasion assays
Forty-eight hours after transfection with siRNAs, cells were counted
and reseeded on the upper face of Transwell migration or invasion
chambers (Thermo Scientific). Cells (40,000–120,000 per chamber)
were seeded in full medium and left at 37°C for 20 h. The same
number of cells was seeded in parallel in 12-well plates and used as
control for seeding variation. Twenty hours later, cells were fixed in
paraformaldehyde (3% in saline), washed, and stained, using crys-
tal violet. Cells attached to the upper face of the chamber were
removed, and only the remaining migrating cells were imaged using
a binocular. ImageJ was used for quantification of migration and
invasion results.
Cell viability assays
MCF10A cells were seeded in 96-well plastic-bottom plates (Greiner)
at 50% confluence, and 24 h later, they were transfected with siRNAs
(30 nM) in six replicates, using Lipofectamine 2000 (Life Technolo-
gies). Seventy-two hours later, cells were treated for 3 h with the
WST-1 reagent (Roche) according to the manufacturer’s instructions.
Absorbance (at 450 nm) was assessed using a Tecan plate reader.
Apoptosis assays
MCF10A cells were seeded in 96-well glass bottom plates (Matrical)
at 50% confluence, and 24 h later, they were transfected with
siRNAs in six replicates (30 nM) using the Lipofectamine 2000
transfection reagent (Life Technologies). Forty-eight hours later,
cells were stained with Hoechst-33258 (Sigma) and apoptotic cells
were stained for activated caspase 3/7 (for 60 min) using NucView-
488 (Biotium). Plates were imaged using an automated ScanR
screening microscope (Olympus). Nuclei and the fraction of apop-
totic cells were counted using the ScanR software.
Gene expression microarrays
Fifteen RNA samples, representing biological duplicates of MCF10A
cells stimulated with EGF (10 ng/ml) for 20, 40, 60, 120, 240, and
480 min, as well as triplicates of non-stimulated cells, were analyzed
using SurePrint G3 Human GE 8×60K one-color microarrays (Agilent
Technologies). The raw data were normalized and filtered in order
to make the experiments comparable with each other and in order to
reduce noise. Furthermore, probes having low-quality measure-
ments were filtered out. Next, for each probe, the log2 ratio of
expression between each time point and time “zero” was calculated.
Genes were considered changing if a fold change of > 0.6 log2 was
observed in at least one time point. Additionally, since many of the
lncRNA probes were based on putative lncRNA annotations, we
overlapped the position of each probe with RefSeq annotated
ncRNAs. Only probes overlapping annotated RefSeq ncRNAs were
retained for assessment of the effect of EGF stimulation on transcript
abundance. The microarray dataset is accessible at the ArrayExpress
database (E-MTAB-4822). In addition, we used DNA arrays to profile
gene expression upon manipulation of LIMT levels. Twelve RNA
samples, representing (i) knockdown of LIMT, (ii) knockdown using
control siRNA (iii) overexpression of LIMT, and (iv) overexpression
of eGFP (all in biological triplicates), were analyzed using
GeneChip Human Gene 2.0 ST Arrays (Affymetrix). The raw data
were normalized and used to identify genes differentially affected by
knockdown versus overexpression of LIMT in MCF10A cells. The
microarray dataset is accessible at the ArrayExpress database
(E-MTAB-4821).
Histone acetylation analysis
Cell fixation, harvest, chromatin immunoprecipitation, library gener-
ation, and sequencing were performed as described (Blecher-Gonen
et al, 2013). For immunoprecipitation, we used a rabbit polyclonal
antibody (ab4729 from Abcam) specific to the acetylated form
(lysine 27) of histone 3. ChIP-seq reads were mapped to the hg37
genome assembly using bowtie2 (Langmead & Salzberg, 2012). Data
presentation used the MACS2 program and fragment size of 270.
Assessment of coding probability
Coding potential was calculated using an alignment-free method,
Coding-Potential Assessment Tool (CPAT), which recognizes coding
and noncoding transcripts from a large pool of candidates (Wang
et al, 2013). Alongside, we used a reference catalog of human
genes, which lists multiple protein-coding sequences (N = 4,000)
and lncRNAs (N = 4,000) (Cabili et al, 2011).
Assessment of the evolutionary conservation of lncRNAs
Evolutionary conservation of the primary nucleotide sequences of
the clinically significant EGF-regulated lncRNAs was calculated by
averaging PhyloP conservation scores (Pollard et al, 2010) of the
exonic regions of each lncRNA using the bigWigAverageOverBED
utility (Kent et al, 2010). As reference, the same analysis was
conducted for all annotated lncRNAs and protein-coding genes
(taken from Ensembl version 82). A more positive score indicates
stronger conservation across various species.
Animal experiments
All animal studies were approved by the Weizmann Institute’s
Animal Care and Use Committee. MDA-MB-231 cells intrinsically
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labeled with RFP and expressing LIMT or eGFP (as control) and
shLIMT or shControl where used to assess tumor growth and
metastasis. For assessment of metastasis formation, 150,000 cells
were injected into the tail vein of 5-week-old female SCID mice.
Eighteen days after injection, lungs were excised and imaged. The
number of metastatic nodules in each lung was calculated using
the Fiji software. For randomization, the weights of all mice were
determined prior to injections and mice were separated into
groups such that the average weight of each group was similar
(average weight 18.2  1.5 g). In order to conduct blind analyses,
images of the excised lung were numbered by an uninvolved
scientist. Animal identity was disclosed only after quantification of
the number of metastatic nodules was made. Samples that fell
outside the 1.5× interquartile range were considered as outliers
and were omitted from further analysis.
Clinical datasets
Three datasets were used. (i) METABRIC (Curtis et al, 2012),
which contains gene expression profiles of  2,000 breast cancer
patients. Profiling was done using Illumina’s gene expression
microarrays and survival of patients was followed for up to
25 years from diagnosis; (ii) a dataset (Gyorffy et al, 2010) that
analyzed patient survival (www.kmplot.com) based on gene
expression and clinical data from Gene Expression Omnibus (GEO).
The version of the online tool we used analyzed 1,660 breast
cancer patients; and (iii) Oslo2, a consecutive study that collects
specimens from breast cancer patients referred to primary surgical
treatment in the Oslo (Norway) region (Aure et al, 2014). For
Oslo2, expression was measured using SurePrint G3 Human GE
8x60K one-color microarrays (Agilent Technologies), according to
the manufacturer’s protocol. For each sample, RNA (100 ng) was
amplified and hybridized to an array, which included 42,405
unique 60-mer probes, targeting 27,958 Entrez genes and 7,419
lncRNAs. Scanning was performed with an Agilent Scanner
G2565A. Signals were extracted using Feature Extraction v.10.7.3.1
(Agilent Technologies). Arrays were log2-transformed, normalized,
and hospital-adjusted by subtracting from each probe value the
median probe value among samples from the same hospital. Probes
with identical Entrez ID were averaged to form a single expression
value per gene. Molecular subtypes of disease were derived using
the PAM50 classifier (Parker et al, 2009). Subtypes were available
for 381 tumors. To evaluate differences in lncRNA expression
between two groups, a Student’s t-test was applied, and to evaluate
differences in expression among three or more groups, a one-way
analysis of variance (ANOVA) was applied. Data from 309 tumors
were available for comparison of lncRNA expression between dif-
ferent clinical subgroups.
Patient survival analyses
Using the METABRIC dataset, the cohort was divided for each probe
into three groups of identical sizes, according to expression level of
the measured lncRNA. A P-value was calculated for the difference in
survival of the highest expressing group, compared to the lowest
expressing group. Using the KM-plotter dataset, high- and low-
expressing groups were defined by the median expression of each
probe in the cohort. In both cases, P-values were corrected for
multiple hypotheses testing (Bonferroni) according to the number of
probes tested in the relevant dataset.
Statistical analysis
The statistical analysis of each assay appears in the relevant figure
legend. For Student’s t-test, unless otherwise indicated, the test was
conducted as a two-sided unpaired test. Bonferroni correction was
used to adjust P-values for multiple hypotheses in relevant cases.
Error bars represent standard deviations. All experiments were
carried out in triplicates, unless specified otherwise.
Expanded View for this article is available online.
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The paper explained
Problem
Breast cancer is a highly heterogeneous disease, the classification and
understanding of which is still incomplete. Further in-depth analysis
of both protein-coding and noncoding genes is vital to accelerate the
resolution of these issues.
Results
Because growth factors play essential roles in both mammary gland
development and in breast cancer progression, and long noncoding
RNAs (lncRNAs) are emerging as cardinal regulators of gene expres-
sion, we profiled epidermal growth factor (EGF) inducible expression
of lncRNAs in normal mammary cells. A subset of the EGF-inducible
lncRNAs we identified correlated with clinical outcome of breast
cancer patients. One of these, a highly conserved lncRNAs we called
LIMT, is downregulated by EGF due to histone deacetylation at the
respective promoter. In agreement with this, LIMT is expressed at low
levels in the basal-like and in the HER2-enriched, two relatively
aggressive subtypes of breast cancer. Furthermore, LIMT was found to
inhibit the migration of mammary cells and to reduce metastasis
formation in vivo.
Impact
In general, our results confirm and extend the roles of lncRNAs in
progression of breast cancer. Specifically, we identify LIMT as a marker
and putative driver of two relatively aggressive subtypes of breast
cancer.
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